short chain dehydrogenase/reductase family 42E, member 2Genealiases: []
Q-omics provides the consensus-scored SDR42E2 profile across patient tissues and cancer cell-line models. SDR42E2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SDR42E2 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, SDR42E2 RNA expression shows 16,038 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUSC, and UVM as cancer lineages where SDR42E2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDR42E2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDR42E2 survival associations across molecular data types. SDR42E2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDR42E2 RNA expression–survival associations across cancer types. High SDR42E2 expression shows unfavorable associations in KIRC, but favorable associations in UCS, SKCM, UCEC, COAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SDR42E2 RNA expression.
This table summarizes SDR42E2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SDR42E2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDR42E2 shows lower tumor expression in LUSC, BRCA, THCA and LUAD and higher tumor expression in LIHC and CHOL. The LUSC box plot shows higher SDR42E2 RNA expression in normal versus tumor tissue (log2 FC = −0.322, t-test p < 0.001).
This table shows molecular features associated with SDR42E2 in patient tissues and cancer cell lines. In patient samples, SDR42E2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SDR42E2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT.
